Drug intelligence / Profile preview

Linfonorm

Development stage
Unknown
Lead developer
Ceres Pharma
Modality
Small Molecules
Administration
Oral
01

Overview

Linfonorm is a multi-ingredient nutraceutical product developed by Amnol, specifically formulated for the management of lymphatic and venous circulation disorders within the field of lymphology. The formulation typically combines bioflavonoids, such as diosmin and rutin, with a standardized extract of Melilotus officinalis (sweet clover) containing coumarin. These components work synergistically to improve microcirculation and lymphatic function. Diosmin and rutin act as vasoprotective agents that increase venous tone and reduce capillary permeability and fragility. Coumarin enhances lymphatic drainage by stimulating the proteolytic activity of macrophages, which facilitates the breakdown and removal of high-protein interstitial fluid characteristic of lymphedema. Linfonorm is primarily used as a supportive treatment for lymphedema and chronic venous insufficiency to reduce edema and improve microvascular health.

Brand names
Linfonorm
Other names
Linfonorm-Amnol-Lymphology
02

Targets

COXCOMT (Catechol-O-methyltransferase)

Beyond the preview

Go deeper on Linfonorm.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Linfonorm.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call